NZ593706A - Use of camptothecin-based compounds for sensitizing tumour cells to radiation - Google Patents
Use of camptothecin-based compounds for sensitizing tumour cells to radiationInfo
- Publication number
- NZ593706A NZ593706A NZ593706A NZ59370606A NZ593706A NZ 593706 A NZ593706 A NZ 593706A NZ 593706 A NZ593706 A NZ 593706A NZ 59370606 A NZ59370606 A NZ 59370606A NZ 593706 A NZ593706 A NZ 593706A
- Authority
- NZ
- New Zealand
- Prior art keywords
- radiation
- tumour cells
- camptothecin
- sensitizing
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000005855 radiation Effects 0.000 title abstract 3
- 210000004881 tumor cell Anatomy 0.000 title abstract 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title abstract 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract 2
- 229940127093 camptothecin Drugs 0.000 title abstract 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title abstract 2
- 230000001235 sensitizing effect Effects 0.000 title abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 230000000637 radiosensitizating effect Effects 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000004696 coordination complex Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- -1 nitro, sulfonyl Chemical group 0.000 abstract 1
- 125000002524 organometallic group Chemical group 0.000 abstract 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72892405P | 2005-10-21 | 2005-10-21 | |
| US11/444,150 US7875602B2 (en) | 2005-10-21 | 2006-05-30 | Camptothecin derivatives as chemoradiosensitizing agents |
| NZ567454A NZ567454A (en) | 2005-10-21 | 2006-10-19 | Camptothecin derivatives as chemoradiosensitizing agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ593706A true NZ593706A (en) | 2012-11-30 |
Family
ID=37963356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ567454A NZ567454A (en) | 2005-10-21 | 2006-10-19 | Camptothecin derivatives as chemoradiosensitizing agents |
| NZ593706A NZ593706A (en) | 2005-10-21 | 2006-10-19 | Use of camptothecin-based compounds for sensitizing tumour cells to radiation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ567454A NZ567454A (en) | 2005-10-21 | 2006-10-19 | Camptothecin derivatives as chemoradiosensitizing agents |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7875602B2 (enExample) |
| EP (1) | EP1951231B1 (enExample) |
| JP (1) | JP5328357B2 (enExample) |
| KR (1) | KR101320160B1 (enExample) |
| CN (1) | CN101300009B (enExample) |
| AU (1) | AU2006304811C1 (enExample) |
| CA (1) | CA2626032C (enExample) |
| ES (1) | ES2428088T3 (enExample) |
| NZ (2) | NZ567454A (enExample) |
| TW (1) | TWI402270B (enExample) |
| WO (1) | WO2007048002A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101402640B (zh) * | 2008-09-02 | 2011-06-15 | 暨南大学 | 双酯化喜树碱衍生物及其制备方法和应用 |
| DE102009004204A1 (de) * | 2009-01-09 | 2010-07-15 | Christian-Albrechts-Universität Zu Kiel | Verfahren zur verbesserten Bioaktivierung von Arzneistoffen |
| US8168648B2 (en) * | 2009-03-06 | 2012-05-01 | Taiwan Liposome Co., Ltd. | Camptothecin derivatives and uses thereof |
| EP2443125B1 (en) * | 2009-06-17 | 2014-11-26 | Threshold Pharmaceuticals, Inc. | Camptothecin derivatives |
| US10391056B2 (en) | 2011-11-03 | 2019-08-27 | Taiwan Lipsome Company, LTD. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
| US10980798B2 (en) | 2011-11-03 | 2021-04-20 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
| US20140135357A1 (en) * | 2012-11-12 | 2014-05-15 | Taiwan Liposome Company, Ltd. | Dose regime for camptothecin derivatives |
| JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
| WO2014130612A1 (en) | 2013-02-20 | 2014-08-28 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| CN108530458A (zh) | 2013-11-01 | 2018-09-14 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10981953B2 (en) | 2013-12-26 | 2021-04-20 | Toagosei Co, Ltd. | Method for promoting expression of calreticulin, and synthetic peptide for use in method for promoting expression of calreticulin |
| JP6872713B2 (ja) | 2015-05-29 | 2021-05-19 | 東亞合成株式会社 | 腫瘍細胞の放射線感受性を増大させる合成ペプチド及びその利用 |
| US10087194B2 (en) | 2015-10-27 | 2018-10-02 | California Pacific Medical Center | Podophyllotoxin derivatives and their use |
| JP6550538B2 (ja) * | 2015-10-27 | 2019-07-24 | カリフォルニア パシフィック メディカル センター | ポドフィロトキシン誘導体およびそれらの使用 |
| EP3509423A4 (en) | 2016-09-08 | 2020-05-13 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| MX2022000474A (es) | 2019-07-11 | 2022-03-11 | Sun Pharma Advanced Res Co Ltd | Derivados de camptotecina con un resto disulfuro y un resto piperazina. |
| CA3169406A1 (en) | 2020-01-28 | 2021-08-05 | Reflexion Medical, Inc. | Joint optimization of radionuclide and external beam radiotherapy |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US554990A (en) * | 1896-02-18 | Target-throwing trap | ||
| US4399282A (en) | 1979-07-10 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5196413A (en) | 1984-12-10 | 1993-03-23 | Johnson Matthey, Inc. | Platinum complexes and the like |
| US4663161A (en) | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
| US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
| US5032617A (en) | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
| US5175278A (en) | 1985-06-28 | 1992-12-29 | Merck & Co., Inc. | Heteropolysaccharide S-657 |
| US4727068A (en) | 1985-10-23 | 1988-02-23 | Johnson Matthey, Inc. | Radiosensitization by cobalt and Fe(III) complexes |
| US5175287A (en) | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
| US4921963A (en) | 1987-04-13 | 1990-05-01 | British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
| US5026694A (en) | 1987-04-13 | 1991-06-25 | The British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
| CA1329206C (en) | 1987-06-10 | 1994-05-03 | Tsutomu Kagiya | Fluorine-containing nitroazole derivatives and radiosensitizer comprising the same |
| US5304654A (en) | 1987-06-10 | 1994-04-19 | Yasunori Nishijima | Fluorine-containing nitroimidazole compounds |
| US4797397A (en) | 1987-07-31 | 1989-01-10 | Warner-Lambert Company | 2-nitroimidazole derivatives useful as radiosensitizers for hypoxic tumor cells |
| US4943579A (en) | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| JPH0819111B2 (ja) | 1987-10-22 | 1996-02-28 | ポーラ化成工業株式会社 | ２―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤 |
| US4954515A (en) | 1988-11-25 | 1990-09-04 | Warner-Lambert Company | Haloalkylaminomethyl-2-nitro-1H-imidazoles |
| US5036096A (en) | 1988-11-25 | 1991-07-30 | Warner-Lambert Company | Aziridino derivatives of nitroimidazoles and pharmaceutical compositions of selected derivatives |
| IL92597A0 (en) | 1988-12-14 | 1990-08-31 | Yasunori Nishijima President K | Novel fluorine-containing 2-nitroimidazole derivatives and radiosensitizer comprising the same |
| US5043165A (en) | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
| US5077057A (en) | 1989-04-05 | 1991-12-31 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5294715A (en) | 1991-02-01 | 1994-03-15 | University Of Pittsburgh | Acridine-intercalator based hypoxia selective cytotoxins |
| CA2097163C (en) | 1992-06-01 | 2002-07-30 | Marianna Foldvari | Topical patch for liposomal drug delivery system |
| MX9304399A (es) | 1992-07-31 | 1994-02-28 | Warner Lambert Co | Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados. |
| US5552156A (en) | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| GB9320781D0 (en) | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
| US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5646159A (en) | 1994-07-20 | 1997-07-08 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
| GB9504065D0 (en) | 1995-03-01 | 1995-04-19 | Pharmacia Spa | Poly-pyrrolecarboxamidonaphthalenic acid derivatives |
| US5736156A (en) | 1995-03-22 | 1998-04-07 | The Ohio State University | Liposomal anf micellular stabilization of camptothecin drugs |
| US6060604A (en) | 1995-03-31 | 2000-05-09 | Florida State University | Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups |
| JPH08333370A (ja) | 1995-06-08 | 1996-12-17 | Kyorin Pharmaceut Co Ltd | 水に可溶な新規フルオロエチルカンプトテシン誘導体、及びその製造方法 |
| US6339091B1 (en) | 1995-06-21 | 2002-01-15 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Comptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues |
| GB9512670D0 (en) | 1995-06-21 | 1995-08-23 | Sod Conseils Rech Applic | Camptothecin analogues |
| CN1211919A (zh) | 1995-09-13 | 1999-03-24 | 佛罗里达州立大学 | 放射增敏性紫杉烷及其药物制剂 |
| WO1997019085A1 (en) | 1995-11-22 | 1997-05-29 | Research Triangle Institute | Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties |
| US5731316A (en) | 1996-01-30 | 1998-03-24 | The Stehlin Foundation For Cancer Research | Derivatives of camptothecin and methods of treating cancer using these derivatives |
| US6096336A (en) | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US5874105A (en) | 1996-01-31 | 1999-02-23 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
| ES2214634T3 (es) | 1996-08-19 | 2004-09-16 | Bionumerik Pharmaceuticals, Inc. | Derivados muy lipofilos de la camptotecina. |
| AU4424797A (en) | 1996-09-18 | 1998-04-14 | Dragoco Inc. | Liposome encapsulated active agent dry powder composition |
| EP0961619A4 (en) | 1996-09-27 | 2001-09-26 | Bristol Myers Squibb Co | HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS |
| US6492335B1 (en) | 1996-09-30 | 2002-12-10 | Bayer Aktiengesellschaft | Glycoconjugates from modified camptothecin derivatives (20-O-linkage) |
| KR100219562B1 (ko) * | 1996-10-28 | 1999-09-01 | 윤종용 | 반도체장치의 다층 배선 형성방법 |
| SG116433A1 (en) | 1996-10-30 | 2005-11-28 | Tanabe Seiyaku Co | S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof. |
| US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| CA2280905C (en) | 1997-02-14 | 2006-08-29 | Bionumerik Pharmaceuticals, Inc. | Highly lipophilic camptothecin derivatives |
| JP3209509B2 (ja) * | 1997-03-28 | 2001-09-17 | インターナショナル・ビジネス・マシーンズ・コーポレーション | ディスク状記録装置及びディスクドライブ装置 |
| ID23424A (id) | 1997-05-14 | 2000-04-20 | Bayer Ag | Glikokonjugat dari 20(s)-kamptotesin |
| GB9721070D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Bioactive derivatives of camptothecin |
| US5935949A (en) | 1998-03-20 | 1999-08-10 | Trustees Of Dartmouth College | Use of androgen therapy in fibromyalgia and chronic fatigue syndrome |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US6057303A (en) | 1998-10-20 | 2000-05-02 | Bionumerik Pharmaceuticals, Inc. | Highly lipophilic Camptothecin derivatives |
| US6207832B1 (en) | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
| US6281223B1 (en) | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| WO2000066127A1 (en) | 1999-05-04 | 2000-11-09 | Bionumerik Pharmaceuticals, Inc. | Novel highly lipophilic camptothecin analogs |
| US6765019B1 (en) | 1999-05-06 | 2004-07-20 | University Of Kentucky Research Foundation | Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids |
| US6228855B1 (en) * | 1999-08-03 | 2001-05-08 | The Stehlin Foundation For Cancer Research | Aromatic esters of camptothecins and methods to treat cancers |
| CA2391534A1 (en) * | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| US6423707B1 (en) | 2000-08-28 | 2002-07-23 | California Pacific Medical Center | Nitroimidazole ester analogues and therapeutic applications |
| US6350756B1 (en) | 2001-01-18 | 2002-02-26 | California Pacific Medical Center | Camptothecin derivatives |
| US6855720B2 (en) | 2001-03-01 | 2005-02-15 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| US6403604B1 (en) | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
| GB0119578D0 (en) | 2001-08-10 | 2001-10-03 | Pharmacia & Upjohn Spa | Fluoro linkers |
| AU2003243380A1 (en) | 2002-06-03 | 2003-12-19 | California Pacific Medical Center | Nitrogen-based homo-camptothecin derivatives |
-
2006
- 2006-05-30 US US11/444,150 patent/US7875602B2/en active Active
- 2006-10-19 KR KR1020087012095A patent/KR101320160B1/ko not_active Expired - Fee Related
- 2006-10-19 JP JP2008536850A patent/JP5328357B2/ja not_active Expired - Fee Related
- 2006-10-19 NZ NZ567454A patent/NZ567454A/en not_active IP Right Cessation
- 2006-10-19 CN CN2006800390612A patent/CN101300009B/zh not_active Expired - Fee Related
- 2006-10-19 EP EP06836448.8A patent/EP1951231B1/en active Active
- 2006-10-19 CA CA2626032A patent/CA2626032C/en active Active
- 2006-10-19 ES ES06836448T patent/ES2428088T3/es active Active
- 2006-10-19 WO PCT/US2006/041175 patent/WO2007048002A2/en not_active Ceased
- 2006-10-19 AU AU2006304811A patent/AU2006304811C1/en not_active Ceased
- 2006-10-19 NZ NZ593706A patent/NZ593706A/xx not_active IP Right Cessation
- 2006-10-20 TW TW095138924A patent/TWI402270B/zh not_active IP Right Cessation
-
2008
- 2008-07-29 US US12/124,712 patent/US8563537B2/en not_active Expired - Fee Related
-
2011
- 2011-01-24 US US13/012,772 patent/US8779138B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009512714A (ja) | 2009-03-26 |
| CN101300009B (zh) | 2013-04-03 |
| EP1951231B1 (en) | 2013-07-31 |
| WO2007048002A3 (en) | 2007-09-13 |
| US20110184009A1 (en) | 2011-07-28 |
| KR20080086436A (ko) | 2008-09-25 |
| AU2006304811A1 (en) | 2007-04-26 |
| AU2006304811C1 (en) | 2012-11-01 |
| ES2428088T3 (es) | 2013-11-05 |
| US8563537B2 (en) | 2013-10-22 |
| EP1951231A4 (en) | 2010-09-22 |
| AU2006304811B2 (en) | 2012-03-22 |
| KR101320160B1 (ko) | 2013-10-23 |
| TW200730532A (en) | 2007-08-16 |
| US20080318873A1 (en) | 2008-12-25 |
| TWI402270B (zh) | 2013-07-21 |
| CN101300009A (zh) | 2008-11-05 |
| HK1115321A1 (en) | 2008-11-28 |
| WO2007048002A2 (en) | 2007-04-26 |
| US20070093432A1 (en) | 2007-04-26 |
| EP1951231A2 (en) | 2008-08-06 |
| US8779138B2 (en) | 2014-07-15 |
| CA2626032A1 (en) | 2007-04-26 |
| NZ567454A (en) | 2011-07-29 |
| US7875602B2 (en) | 2011-01-25 |
| JP5328357B2 (ja) | 2013-10-30 |
| CA2626032C (en) | 2011-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ593706A (en) | Use of camptothecin-based compounds for sensitizing tumour cells to radiation | |
| Awadallah et al. | Inhibition studies on a panel of human carbonic anhydrases with N 1-substituted secondary sulfonamides incorporating thiazolinone or imidazolone-indole tails | |
| RU2497807C2 (ru) | Карбазольные соединения и терапевтические применения соединений | |
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| WO2021079302A1 (en) | Pharmaceutical combination of prmt5 inhibitors | |
| TW200942541A (en) | Polysubstituted 6-heteroarylimidazo[1,2-α]pyridine derivatives, preparation thereof and therapeutic use thereof | |
| Sun et al. | Synthesis and antitumor activity of 1, 3, 4-oxadiazole possessing 1, 4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors | |
| WO2012061557A3 (en) | Chemical compounds | |
| MY149622A (en) | Pyrazoles as 11-beta-hsd-1 | |
| GB2433070A (en) | Porphyrin derivatives and their use in photon activation therapy | |
| WO2004108139A3 (en) | Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer | |
| NO20085217L (no) | Effektive pyrimidinderivater i behandlingen av kreft | |
| NO20044995L (no) | Heterosykliske forbindelser | |
| GEP20125469B (en) | Inhibitors of akt activity | |
| PE20060504A1 (es) | Derivados de pirimidina en el tratamiento de cancer | |
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| Abdellattif et al. | Novel 2-hydroselenonicotinonitriles and selenopheno [2, 3-b] pyridines: Efficient synthesis, molecular docking-DFT modeling, and antimicrobial assessment | |
| MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. | |
| WO2008033891A3 (en) | Azonafide derived tumor and cancer targeting compounds | |
| Alam | New 1, 2, 4-triazole based eugenol derivatives as antiCOX-2 and anticancer agents | |
| US20230066014A1 (en) | Substituted nucleoside analogs as prmt5 inhibitors | |
| Chen et al. | A novel photocaged B-RafV600E inhibitor toward precise melanoma treatment | |
| Küçükbay et al. | Preparation, carbonic anhydrase enzyme inhibition and antioxidant activity of novel 7-amino-3, 4-dihydroquinolin-2 (1H)-one derivatives incorporating mono or dipeptide moiety | |
| Afreen et al. | Thiazole-and Coumarin-Conjugated (β-Lactam Scaffold) Azetidinones Synthesis and Their Substitution Effect in In Silico, and In Vitro Cell Viability Studies | |
| Pagilla et al. | Identification of novel quinazolinone hybrids as cytotoxic agents against C6 glioma cell lines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 OCT 2013 BY CPA GLOBAL Effective date: 20130627 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 OCT 2016 BY CPA GLOBAL Effective date: 20130913 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 OCT 2017 BY CPA GLOBAL Effective date: 20161007 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 OCT 2018 BY CPA GLOBAL Effective date: 20170929 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 OCT 2019 BY CPA GLOBAL Effective date: 20181018 |
|
| LAPS | Patent lapsed |